They will review your weight history, metabolic markers, medication history, comorbid conditions, and long-term goals to determine whether an extended dosing interval is suitable for you
Depending on your situation, other medications may be appropriate: Tirzepatide (brand name Mounjaro or Zepbound) is a dual GLP-1/GIP receptor agonist that has shown even greater weight loss in clinical trials
One standout feature of Zepbound is its capacity to sustain weight loss
If appetite changes are making it hard to keep up with nutrition, GLP-1 Daily Support may be worth exploring
Sports Medicine , 46(10), 1419-1449
OneSource Specialty Pharma is investing approximately $100 million to expand its drug-device facilities, increasing cartridge filling capacity from 40 million to 200 million units over the next 1824 months